Passive therapy with humanized anti-staphylococcal enterotoxin B antibodies attenuates systemic inflammatory response and protects from lethal pneumonia caused by staphylococcal enterotoxin B-producing Staphylococcus aureus.
PubWeight™: 0.75‹?›
Published in Virulence on December 07, 2016
Authors
Melissa J Karau1, Mulualem E Tilahun2,3, Ashton Krogman4, Barbara A Osborne2, Richard A Goldsby3, Chella S David4, Jayawant N Mandrekar5, Robin Patel1,6, Govindarajan Rajagopalan4,6
Author Affiliations
1: a Division of Clinical Microbiology , Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , Rochester , MN , USA.
2: b Department of Veterinary and Animal Sciences , University of Massachusetts , Amherst , MA , USA.
3: c Department of Biology , Amherst College , Amherst , MA , USA.
4: d Department of Immunology , Mayo Clinic College of Medicine , Rochester , MN , USA.
5: e Division of Biomedical Statistics and Informatics , Department of Health Sciences Research , Mayo Clinic College of Medicine , Rochester , MN , USA.
6: f Division of Infectious Diseases , Department of Medicine , Mayo Clinic College of Medicine , Rochester , MN , USA.